Paratek Pharmaceuticals was hit with a shareholder lawsuit on Sept. 15 in Delaware Court of Chancery over the company’s proposed acquisition by Novo Holdings and Gurnet Point Capital for $462 million. The suit was filed by Bernstein Litowitz Berger & Grossman, Kessler Topaz Meltzer & Check and Brodsky Smith on behalf of Michael Francis Scarcello, who seeks to inspect the company’s books and records in connection with the deal. According to the complaint, the proxy statement filed in support of the deal contains misleading information. Counsel have not yet appeared for the defendant. The case is 2023-0941-, Michael Francis Scarcello v. Paratek Pharmaceuticals, Inc.
This suit was surfaced by Law.com Radar, a source for high-speed legal news and litigation updates personalized to your practice. Law.com Radar publishes daily updates on just-filed federal cases like this one. Click here to get started and be first to know about new suits in your region, practice area or client sector.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
